GATT Technologies BV

Made from synthetic polymer technology, ETHIZIA is an adjunctive haemostat solution designed to achieve sustained haemostasis in difficult to control bleeding conditions Ethicon has received European approval for ETHIZIA sealing patch. (Credit: Debora Alves from Pixabay) Johnson & Johnson MedTech’s Ethicon, a surgical instruments maker, has received the CE Mark for the ETHIZIA haemostatic sealing patch. ETHIZIA is an adjunctive haemostat solution designed to achieve sustained haemostasis in difficult to control bleeding conditions. Made from synthetic polymer technology, the sealing patch is said to be the first and only haemostatic matrix designed to be equally effective and active on both sides. According to Ethicon, the patch allows easy handling in both open and minimally invasive procedures due to its maximum adaptability design. Additionally, ETHIZIA can be packed, rolled, pulled apart, trimmed, and tailored. The haemostatic sealing patch stopped bleeding in 30 seconds in 80% of the patients who were examined in a clinical trial. The results were equal to an average of six times faster than the leading Fibrin Sealant Patch, the Johnson & Johnson MedTech company said. Ethicon company group chairman Vladimir Makatsaria said: “As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions. “Disruptive bleeding can contribute to serious complications, and with the addition of ETHIZIA to our portfolio, we are well positioned to deliver critical haemostasis solutions for patients.” The surgical instruments maker has received European approval for the sealing patch as an adjunctive haemostat for internal organs’ disruptive bleeding with the exception of cardiovascular and neurological. With regulatory permissions in place, ETHIZIA is anticipated to launch in Q1 2024 across Europe, the Middle East and Africa (EMEA) and other markets in North America, Asia–Pacific (APAC), and Latin America. In May last year, Ethicon acquired Netherlands-based GATT Technologies, which is engaged in the development of haemostatic and sealant products by using synthetic polymer to handle difficult surgical bleeding and leak issues. The synthetic technology from GATT and the company’s acquisition enhances Ethicon’s existing capabilities to create new solutions including ETHIZIA haemostatic sealing patch for critical unmet needs.

Addition of hemostatic patch complements Ethicon's comprehensive Biosurgery portfolio and ability to address critical unmet needs in controlling bleeding RARITAN, N.J., Nov. 15, 2023 /PRNewswire/ -- Ethicon*, a Johnson & Johnson MedTech company**, today announced the approval of ETHIZIA™, an adjunctive hemostat solution which has been clinically proven to achieve sustained hemostasis in difficult to control bleeding situations.1 Comprised of unique synthetic polymer technology, ETHIZIA™ Hemostatic Sealing Patch is the first and only hemostatic matrix designed to be equally active and efficacious on both sides***.2 Designed for maximum adaptability, it can be stuffed, rolled, pulled apart, trimmed and tailored,3, 4 making it easy to handle in both open and minimally invasive surgeries.5 In 80% of clinical trial patients studied****, ETHIZIA™ Hemostatic Sealing Patch stopped bleeding in 30 seconds, an average of six times faster than the leading Fibrin Sealant Patch*****.6 7 ETHIZIA™ Hemostatic Sealing Patch has received CE Mark approval as an adjunctive hemostat for disruptive bleeding on internal organs, except cardiovascular and neurological, and is expected to launch in EMEA in Q1 2024, and other key markets in North America, APAC and LATAM following regulatory approvals. "As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions," said Vladimir Makatsaria, Company Group Chairman, Ethicon. "Disruptive bleeding can contribute to serious complications, and with the addition of ETHIZIA™ to our portfolio, we are well positioned to deliver critical hemostasis solutions for patients." In May 2022, Ethicon acquired GATT Technologies B.V., a Netherlands-based company using differentiated synthetic polymer to create hemostatic and sealant products to address complex surgical bleeding and leak challenges. The acquisition of GATT and the addition of its synthetic technology complements Ethicon's current capabilities, enabling the development of innovative solutions that address critical unmet needs, such as ETHIZIA™ Hemostatic Sealing Patch which can offer sustained hemostasis in difficult to control bleeding situations. As a global leader in surgery, Ethicon harnesses deep expertise to design surgical solutions that are smarter, less invasive, and more personalized. The introduction of ETHIZIA™ provides a unique design that surgeons can trust to work equally effective on both sides*** 8, giving surgeons the confidence they need in any surgical situation. About Ethicon At Ethicon, a Johnson & Johnson MedTech company, putting humanity at the core of care is our passion and our purpose. In collaboration with clinicians and health care experts around the world, we develop clinically-differentiated surgical technologies and solutions to help address some of the most pressing health challenges of our time such as metabolic disease, cardiovascular disease and cancer. Through our efforts and ingenuity, we aspire to elevate standards of care and create a healthier future for the patients of today and tomorrow. Visit to learn more about us. About Johnson & Johnson MedTech At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more, visit . Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the ETHIZIATM adjunctive hemostat solution. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ethicon, Inc., Ethicon Endo-Surgery, LLC, Johnson & Johnson Enterprise Innovation Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of Ethicon, Inc., Ethicon Endo-Surgery, LLC, Johnson & Johnson Enterprise Innovation Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. *Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. All other trademarks are the property of their respective owners. **Johnson & Johnson MedTech comprises the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson's MedTech segment. ***Pre-clinical test data are not necessarily indicative of clinical performance. ****Based on clinical trial data. The Full Analysis Set showed 32/39 patients (82%) achieved hemostasis in 30 seconds. *****Tachosil Fibrin Sealant Patch is leading in EMEA region based on market share data. Tachosil time to hemostasis is 3 min per IFU. Media Contact: Paloma Feliciano [email protected] Investor Contact : Sarah Wood [email protected] ©Ethicon US, LLC. 2023. All Rights Reserved. Logo -

DUBLIN--( BUSINESS WIRE )--The "Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. SAH global market is expected to grow at mid-single digit CAGR from 2022 to 2029 to reach $4,366.0 million by 2029 The SAH global market is mainly segmented based on products, applications, end-users, and based on geography. The product market is segmented into sealant, adhesive and hemostat. Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. The sealants are further segmented based on their origin into natural and synthetic sealants. The synthetic sealant accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. The natural sealants are further sub-segmented based on composition into fibrin and albumin sealants. Among them, fibrin accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. The synthetic sealants are further segmented based on composition into cyanoacrylate, hydrogels, and others. Among them, hydrogels accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. The adhesive market is segmented into natural and synthetic adhesives, among them; synthetic adhesives accounted for the largest revenue in 2022 and are expected to grow at low-single digit CAGR from 2022 to 2029. The natural adhesives are further sub-segmented based on composition into fibrin and albumin, among them, fibrin adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. The synthetic adhesives are further segmented based on composition into cyanoacrylate and polyurethane. The cyanoacrylate adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. Hemostats are classified based on function into mechanical hemostats, active hemostats, flowable hemostats, and fibrin sealants hemostats, among them, the mechanical hemostats accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. Fibrin sealant hemostat is the fastest growing segment at high-single digit strong CAGR from 2022 to 2029 because it is unique, powerful and effective for localized and diffused bleeding during surgical procedures. The application market is segmented into Cardiovascular surgery, General Surgery, Orthopedic surgery, Urology, Pulmonology, Neurosurgery, Gynecology, Cosmetic surgery and Others. The general surgery segment accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029, because of high demand for various surgical procedures. Cosmetic surgery is the fastest growing segment at high-single digit CAGR, because of the advancements in treatment regimes available and better cosmetic outcomes. The end-users market is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment accounted for the largest share in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029, due to an increase in the aging population, increase in surgical procedural volumes, and better patient care services with advanced facilities. Factors Influencing Market Drivers and Opportunities Increasing Demand for Surgical Procedures Boosts Sah Market Growth the Emergence of Technically Advanced Products Increasing Geriatric Population Acquisition to Open An Array of Opportunities for the Market to Flourish Acceptance of Sah and Market Expansion in Emerging Nations Restraints and Threats Pitfalls in the Usage of Sah Expensive Sah Impeding Effective Penetration in Low and Middle-Income Countries Unfavorable Reimbursement Policies in Developing Nations Stringent Regulatory Guidelines Availability of Alternative Products Major Companies Advanced Medical Solutions Artivion Baxter International, Inc B.Braun Melsungen AG Becton, Dickinson and Company (C.R.Bard Inc.) Corza Medical Integra Lifescience Johnson & Johnson (Ethicon) Medtronic, plc Teleflex Regulatory Affairs International Organization for Standardization Iso 9001: 2015 Quality Management System Iso 14644-1 Cleanroom Standards Iso 13485 Medical Devices Iso 10993 Biological Evaluation of Medical Devices Astm International Standards U.S. Canada Europe Japan China India Technological Advancements Bioglue Bioinspired Glue from Barnacles Snake-Derived Super Glue Alga Mimetic Technology a Polymer Patch for the Abdominal Cavity Clinical Trials Scope of the Market Surgical Sealants, Adhesives and Hemostats Global Market, Based on Product Sealants Natural Sealants Fibrin Natural Sealants Albumin Natural Sealants Synthetic Sealants Cyanoacrylate Hydrogels Others Adhesives Natural Adhesives Fibrin Natural Adhesives Albumin Natural Adhesives Synthetic Adhesives Cyanoacrylate Polyurethane Hemostats Mechanical Hemostats Active Hemostats Flowable Hemostats Fibrin Sealant Hemostats Surgical Sealants, Adhesives and Hemostats Global Market, Based on Application Cardiovascular Surgery General Surgery Orthopedic Surgery Urology Pulmonology Neurosurgery Gynecology Cosmetic Surgery Others Surgical Sealants, Adhesives and Hemostats Global Market, Based on End-Users Hospitals Ambulatory Surgical Centers Others Companies Mentioned Adhezion Biomedical, LLC Advanced Medical Solutions Group plc (Selantis) Aegis-Lifesciences Artivion (Cryolife) Axio Bioscience B.Braun Melsungen AG Baxter International, Inc. Becton Dickinson and Company (Tissumed) Beaver Visitec International Betatech Medical Biocer Entwicklungs-Gmbh Biom'Up Boz Medical Chemence Medical, Inc. Corza Medical CSL Behring Dalim Tissen Dsi Ltd Equimedical Gatt Tech Gelita Medical Gem Srl Glustitich, Inc. Green Cross Biopharma Grena Grunenthal GmbH (Adhesys Medical Gmbh) H.B. Fuller Hager & Werken GmbH & Co. Kg Haulan Bioengineering Co Ltd Healthium Hemarus Therapeutics Hemostatis Ibc Pharmaceuticals, Ltd. Integra Lifesciences Holding Corporation Johnson & Johnson (Ethicon) Katsan Medical Devices Medtronic Meril Life Sciences Pvt. Ltd Ocular Therapeutix, Inc. Optmed, Inc. Peter Surgical Pfizer Reliance Lifescience Samyang Holdings Corporation Shanghai Raas Starsil Hemostat Stryker Symatese Teleflex Terumo Corporation Theracion Biomedical Tissium (Gecko Medical) Tricol Biomedical Vivostat A/S Wortham Laboratories Inc Zhejiang Perfectseal For more information about this report visit https://www.researchandmarkets.com/r/u7svcu